FDA briefing documents posted ahead of Wednesday’s meeting of the Cardiovascular and Renal Drugs Advisory Committee (adcom) meeting to review the approvability of cangrelor were sufficiently positive to give shares of The Medicines Co. (NASDAQ:MDCO) a modest boost Monday.